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Colorectal cancer (CRC) is the fourth most common cause of death worldwide. Surgery
is usually the first line of treatment for patients with CRC but many tumors with similar
histopathological features show significantly different clinical outcomes. The discovery of
robust prognostic biomarkers in patients with CRC is imperative to achieve more effective
treatment strategies and improve patient’s care. Recent progress in next generation
sequencing methods and transcriptome analysis has revealed that a much larger part
of the genome is transcribed into RNA than previously assumed. Collectively referred
to as non-coding RNAs (ncRNAs), some of these RNA molecules such as microRNAs
(miRNAs) and long non-coding RNAs (lncRNAs) have been shown to be altered and
to play critical roles in tumor biology. This discovery leads to exciting possibilities for
personalized cancer diagnosis, and therapy. Many lncRNAs are tissue and cancer-type
specific and have already revealed to be useful as prognostic markers. In this review, we
focus on recent findings concerning aberrant expression of lncRNAs in CRC tumors and
emphasize their prognostic potential in CRC. Further studies focused on themechanisms
of action of lncRNAs will contribute to the development of novel biomarkers for diagnosis
and disease progression.
Keywords: long non-coding RNA, ncRNA, prognostic marker, colorectal cancer, biomarker
INTRODUCTION
Need for Prognostic Markers in Colorectal Cancer
Colorectal cancer (CRC) is among the most commonly diagnosed cancers worldwide. In 2012,
according to the GLOBOCAN estimations, there were 1.3 million new cases of CRC worldwide
(Ferlay et al., 2015). That year, around 694,000 patients died of the disease, accounting for 8.5% of
all cancer deaths, and ranking CRC the fourthmost common cause of death from cancer. Colorectal
cancer develops as a result of the pathologic transformation of normal colonic epithelium to
adenomatous polyp, which ultimately leads to invasive cancer (Jass, 2006). Tumor induction
and progression is considered a stepwise process with the accumulation of different genetic and
epigenetic alterations. Most tumors (85%) are generated by chromosomal instability and are
associated with high frequency aneuploidy and allelic imbalance. The prognosis and survival of
CRC patients are clearly related to the degree of penetration of the tumor through the bowel
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wall, and to the presence or absence of nodal involvement
and distant metastases. The American Joint Committee on
Cancer’s TNM (Tumor size, lymph Node involvement, and
distant Metastasis) staging system is the current standard for
determining the prognosis of patients with CRC. After diagnosis,
staging (stages I to IV) is performed based on the extent of
penetration of the colorectal cancer into the layers forming the
wall of the colon and whether the tumor cells have spread to
lymph nodes and other organs. This classification is important
for planning patient treatment. The gold standard therapy for
resectable tumors is surgery, whereas adjuvant chemotherapy is
indicated only in patients with a high risk of disease recurrence.
Traditional prognostic factors for malignancy include clinical
and pathological criteria such as patient’s age, tumor size, and
tumor grade, number of affected local lymph nodes, and presence
and grade of metastasis. Although these factors have been used
for decades, they have serious limitations in predicting patient
outcome (Burke, 2004). In stage II the tumor is confined to
the bowel wall in contrast to stage III and IV, in which the
tumors have disseminated to local lymph nodes and distant
organs, respectively. The majority of patients with stage II do
not receive adjuvant chemotherapy treatment since, at present
there is no evidence for beneficial effect for this patient group as
a whole. From all those patients receiving treatment, only a small
proportion (1–5%) derives clinical benefit, whereas adverse side
effects are common (Aranha and Benson, 2007). Nevertheless,
20–25% of all stage II CRC patients will present with recurrent
disease and subsequent death from disease within 5 years after
primary surgery (Benson et al., 2004). On the other hand,
adjuvant treatment is universally recommended for all patients
with stage III disease, for whom the cancer has already spread to
the surrounding lymph nodes.
Thus, there is a need to add prognostic and predictive markers
to the current staging system. In the last two to three decades,
hundreds of cancer biological prognostic markers for CRC cancer
have been proposed such as, microsatellite instability (Popat
et al., 2005), chromosomal instability (Pino and Chung, 2010), K-
ras mutation (Rui et al., 2013), mRNA and microRNA expression
profile (Nugent et al., 2011; Salazar et al., 2011; Sanz-Pamplona
et al., 2012). Although they have shown a potential in this
field, validation studies are still required and, to date, there is
insufficient evidence to recommend the routine clinical use of any
of these putative biomarkers. Therefore, the discovery of robust
prognostic and/or predictive biomarkers in patients with CRC is
imperative for advancing treatment strategies for the disease and
improving patient care.
In this review, we provide an overview of recent findings
concerning the prognostic potential of lncRNAs in CRC.
LncRNAs in Cancer and Their Potential As
Prognostic Biomarkers
Recent progress in next generation sequencing methods and in
transcriptome analysis has shown that a much larger portion of
the genome is transcribed into RNA than previously assumed
(Consortium, 2012). Long non-coding RNAs (lncRNAs) are a
widespread class of expressed RNA transcripts longer than 200
nucleotides, that have no coding potential but that, similar to
protein coding genes, are typically polyadenylated, transcribed
by RNA polymerase II, and spliced (Ponting et al., 2009; Ulitsky
and Bartel, 2013). Compared to protein-coding genes, they are
expressed at lower levels and in a more tissue-specific manner
(Derrien et al., 2012). Initially, lncRNAs were thought to be
simply the result of transcriptional noise, but recent studies
point to a crucial involvement of a growing number of lncRNAs
in central cellular processes such as epigenetic modulation,
transcription, and translation (Mercer and Mattick, 2013;
Johnsson et al., 2014). During the last decade, the rapid advance
in sequencing and array technologies has further facilitated
the study of these molecules regarding their involvement in
pathological processes. In this context, recent studies show a
clear implication of some lncRNAs in the development of various
diseases, ranging from neurodegeneration to cancer (Wapinski
and Chang, 2011).
Recent large-scale sequencing efforts such as the International
Cancer Genomics Consortium and the Cancer Genome Atlas,
as well as numerous small-scale projects, have focused on the
detection of somatic genetic and epigenetic alterations that
are tightly associated with the disease. These studies have
revealed that a significant fraction of such alterations lie in non-
coding parts of the genome, often affecting lncRNA loci. Such
alterations can involve deletions, differences in copy number,
point mutations but also regulatory changes that can lead
through different modes of action to changes in gene expression.
For example, MALAT1, a lncRNA with an important role
in cell proliferation, migration and invasion, has been found
significantly up-regulated in several cancers, including lung,
breast, prostate, liver, and colon. Many cancer-relevant genes,
in particular tumor suppressor genes, encompass long antisense
ncRNAs (Nie et al., 2012), and some evolutionarily conserved
non-coding transcripts are altered in human cancer, such as
leukemia and other carcinomas (Calin et al., 2007). The finding
that alterations in sequence or expression of some lncRNAsmight
be associated to specific stages of cancer progression paves the
way for their use as prognostic biomarkers (Hu et al., 2014).
Several studies have indicated dysregulation of lncRNA
expression in CRC tumors and a potential functional impact
in pathogenesis and clinical implications. These studies are
quite heterogeneous, including association studies in large-scale
sequencing projects as well as detailed analyses of the direct
involvement of particular lncRNAs in the progression of the
disease. Overall, the precise molecular mechanisms underlying
CRC pathogenesis remain to be fully elucidated, with still a
limited number of lncRNAs with a well-characterized molecular
mechanism of action. The review of these few known molecular
mechanisms is beyond the scope of this paper, and we direct
the interested reader to recent reviews in that topic (Gutschner
and Diederichs, 2012; Zhang K. et al., 2014). Besides, there are a
growing number of new lncRNAs with unknown functions, and
whose implications in tumor biology are not fully understood.
For instance, a recent study based on 7256 RNA-seq libraries
from tumors, normal tissues and cell lines, identified a total
of 196 non-coding transcripts associated with CRC, but the
vast majority of them (163) were previously unknown (Iyer
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et al., 2015). Imbalances in expression levels may be used to
identify new potential markers for disease progression. However,
further analyses will be needed to address whether alterations in
sequence or expression of some lncRNAs are involved in special
biological processes relevant to cancer.
In the present review, we focus on studies investigating
whether lncRNAs can serve as prognostic biomarkers for CRC
(Table 1; Figure 1), and we will discuss recent advances in the
potential value of lncRNAs to predict outcomes of CRC patients
(Table 2). The candidate lncRNAs reviewed below may add
prognostic power to the current gold-standard AJCC (American
Joint Committee on Cancer) staging system.
ONCOGENIC LncRNAs ASSOCIATED WITH
PROGNOSIS IN COLORECTAL CANCER
91H
The “H19 antisense long, non-coding RNA” 91H is a 120 kb
antisense long non-coding transcript spanning the H19 gene
locus. 91H expression has been associated with breast cancer
(Berteaux et al., 2008) and esophageal squamous cell carcinoma
progression (Gao et al., 2015). Deng et al. (2014) found
91H transcript over-expression in CRC tissues compared with
adjacent non-cancerous tissue, as well as CRC cell lines
compared with normal intestinal epithelial cell line. The authors
showed that in vitro knockdown of 91H inhibited cell motility,
migration and invasiveness of CRC cells lines. Finally, they
observed that elevated expression of 91H was associated with
poor prognosis and distant metastasis in patients with CRC
(Deng et al., 2014).
CCAT1
Colon Cancer Associated Transcript-1 (CCAT1) was first
described as an 11.88 kb lncRNA highly expressed in CRC
compared to normal tissue (Nissan et al., 2012). CCAT1 is
transcribed from a locus in chromosome 8q24.21, located 515 kb
upstream of the well-known transcription factor c-Myc, and
reported to be a “hot-spot” locus with many genetic alterations
in colorectal cancer (Zanke et al., 2007; Haerian et al., 2011).
Recently, Qiu and Yan (2015) analyzed a cohort of five published
datasets including 355 samples, validating the association of
CCAT1 with CRC (Qiu and Yan, 2015). CCAT1 up-regulation is
present in the vast majority of primary CRC tumors, including
pre-cancerous polyps (adenomas), lymph nodes, blood, and
distant CRC metastasis. Increased expression of CCAT1 has been
correlated with patient’s clinical stage, lymph node metastasis,
and survival time. Taking the information together, it suggests
that CCAT1 could have key roles in both tumorigenesis and
metastasis, and thus it may be a good candidate as a clinical
outcome biomarker (Alaiyan et al., 2013; He et al., 2014).
Indeed, a recent study showed that CCAT1 levels were not
only significantly higher in plasma of CRC patients compared
to control individuals but also significantly decreased in CRC
patients after surgical treatment (Zhao et al., 2015). The authors
established by means of ROC analysis that plasma CCAT1
provided a strong separation between CRC patients and the
control group (AUC = 0.836, P < 0.001), an effective
screening which improved when combining plasma levels of
CCAT1 and HOTAIR (AUC = 0.954, P < 0.001). In addition,
this combination of CCAT1 and HOTAIR levels in plasma
could detect CRC at an early stage (85%), demonstrating that
increased plasma levels of CCAT1 (especially when combined
with HOTAIR) could be used as a predictive biomarker for CRC
screening (Zhao et al., 2015).
CLMAT3
Cancer Liver Metastasis Associated Transcript-3 (CLMAT3) is
a long non-coding RNA that recently emerged as a potential
independent prognostic factor in CRC with liver metastasis (Ye
et al., 2015). Almost half of the CRC patients with advanced CRC
will suffer colorectal liver metastasis during the disease course,
and so far there are no available early prognostic biomarkers that
enable the screening of CRC patients suffering liver metastasis.
To that end, a new study aimed to profile the expression levels
of lncRNAs in a total of 264 CRC samples with or without liver
metastasis (synchronous and metachronous). First, the authors
identified 40 lncRNAs differentially expressed in the discovery
phase. Next, they validated three novel lncRNAs (TR140014124,
TR01015341, and TR05005298, further termed CLMAT1 to 3
respectively) by RT-qPCR in an independent cohort. Finally,
they found that lncRNA CLMAT3 located in chromosome 14
(chr14:101379770-101381326, Hg19) was the most up-regulated
lncRNA and that its high expression was significantly associated
with liver metastasis and lymph node metastasis. In addition,
the patients with tumors displaying high lncRNA-CLMAT3
expression exhibited shorter overall survival than those with low
lncRNA-CLMAT3 expression tumors. Furthermore, the results of
multivariate analysis indicated that lncRNA-CLMAT3 expression
was an independent prognostic indicator of CRC patient’s
survival compared with CRC patients with liver metastasis (Ye
et al., 2015). However, these results need to be proven in a larger
cohort, including a heterogeneous population, and whose 5-year
overall survival rate is confirmed.
DANCR
Differentiation Antagonizing Non-Protein Coding RNA
(DANCR) is a 7.94 RNA gene, mapping on chr4q12, and
associated to stem cell-like state. It has been shown to be involved
in maintenance of undifferentiated cell state of epidermis (Kretz
et al., 2012) and osteoblasts (Zhu and Xu, 2013; Jia et al., 2015).
Two recent studies suggest a novel mechanism of tumorigenesis
involving this lncRNA in hepatocellular carcinoma (Yuan et al.,
2016) and in colorectal cancer (Liu et al., 2015), respectively. The
former shows thatDANCR actionmay increase stemness features
and offer a potential prognostic marker and a therapeutic target
for hepatocellular carcinoma. The latter quantifies the expression
of lncRNA DANCR in a total of 104 CRC tissues and adjacent
non-tumor tissues by qRT-PCR, and analyzes the correlation
with the clinicopathological characteristics and outcome of the
CRC patients included in the study. As a result, the authors show
a remarkably higher expression of lncRNA DANCR in CRC
tissues compared with adjacent non-tumor tissues (P < 0.05),
and show that these values are significantly associated with TNM
stage, histologic grade and lymph node metastasis (P < 0.05),
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TABLE 1 | Description of potential prognostic lncRNA markers in colorectal cancer.
LncRNA Genomic location Gene size (kb) Locus Type Function in tumorigenesis of CRC and
mechanism of action
References
ONCOGENIC lncRNA
91H Chr11p15 119.32 H19/IGF2 AS Proliferation, migration and invasion. Deng et al., 2014
CCAT1 Chr8q24.21 11.88 c-MYC – Progression and metastasis mediated by c-Myc
binding to CCAT1 promoter region.
Nissan et al., 2012; Alaiyan
et al., 2013; He et al., 2014;
Zhao et al., 2015
CLMAT3 Chr14q32.31 1.55 SPARC – Progression and metastasis. Ye et al., 2015
DANCR Chr4q12 7.94 – – Progression and metastasis. Liu et al., 2015
FEZF1-AS1 Chr7q31.32 6.42 FEZF1 AS Proliferation, migration and invasion through
S-phase entry.
Chen et al., 2016
FTX ChrXq13.2 329.62 XIC lincRNA Proliferation, migration, and invasion mediated
by Xist up-regulation.
Guo X. B. et al., 2015
HOTAIR Chr12q13.13 12.64 HOXC AS Migration, and invasion through
Polycomb-mediated chromatin modifications,
and EMT molecules interaction.
Rinn et al., 2007; Kogo et al.,
2011; Wu Z. H. et al., 2014;
Zhang S. et al., 2014; Zhao
et al., 2015
HOTTIP Chr7p15.2 8.68 HoxA AS Progression and metastasis through G1 phase
arrest, S phase reduction, and apoptosis
promotion through p21 inactivation.
Ren et al., 2015; Lian et al.,
2015
lncRNA-ATB Chr14q11.2 2.73 – – Promotion of invasion and metastasis via
interaction with transcription factors ZEB1 and
ZEB2, involved in EMT in other cancer types.
Yuan et al., 2014; Iguchi et al.,
2015
MALAT1 Chr11q13.1 8.75 NEAT-2 lincRNA Proliferation, migration, and invasion through
release of proto-oncogene PTBP2, and
interaction with AKAP-9 protein, and
Wnt/β-catenin signaling pathway proteins.
Ji et al., 2013; Smolle et al.,
2014; Ji et al., 2014; Yang
et al., 2015
PCAT1 Chr8q24.21 173.96 – lincRNA Potential promotion of metastasis through
interaction with BRCA2 and PRC2 in other
cancer types.
Prensner et al., 2011; Ge
et al., 2013
PVT1 Chr8q24.21 306.72 PVT1 lincRNA Proliferation, invasion, and antiapoptotic effect
via modulation of chromatin remodeling
complex SWI/SNF.
Takahashi et al., 2014
TUG1 Chr22q12.2 9.7 TUG1 lincRNA Progression and metastasis mediated by
modulation of the expression of EMT related
genes.
Sun et al., 2016
UCA1 Chr19p13.12 7.37 UCA1 lincRNA Proliferation, and antiapoptotic effect through
G0/G1 growth arrest.
Han et al., 2014
TUMOR SUPPRESSIVE lncRNA
GAS5 Chr1q25.1 4.98 GAS5 – Inhibition of cell proliferation by mimicking
glucocorticoid response element (GRE).
Mourtada-Maarabouni et al.,
2010; Yin et al., 2014
LINC01296 Chr22q11.1 20.55 – lincRNA Potential epigenetic silencing mechanism. Qiu and Yan, 2015
MEG3 Chr14q32.2 81.62 DLK1-MEG3 lincRNA Prevents abnormal proliferation by promoting
p53 expression.
Zhang et al., 2003; Zhou
et al., 2007; Yin et al., 2015
NcRAN Chr17q25.1 7.58 SNHG16 AS Involved in migration and invasion. Qi et al., 2015; Smolle et al.,
2014
ncRuPAR Chr5q13.3 0.48 ncRuPAR lncRNA Involved in invasion and metastasis. Yan et al., 2014
RP11-462C24.1 Chr4q25 82.27 RPL34 AS Involved in invasion, and metastasis. Shi et al., 2014
TUSC7 Chr3q13.31 14.34 LSAMP lincRNA Growth suppressor through regulation of
apoptotic and cell cycle transcripts in
osteoblasts. No mechanism described in CRC.
Qi et al., 2013
Abbreviations: AS, antisense; EMT, Epithelial-mesenchymal transition; lincRNA, long intergenic non-coding RNA.
with no significant correlation with other clinical features such as
gender, age, tumor size, and local invasion (P > 0.05). Moreover,
the authors suggest that lncRNA DANCR expression could be
an independent prognostic indicator for overall survival (HR =
2.131, 95% CI, 1.157–7.058; P = 0.009) and disease-free survival
(HR = 2.397, 95% CI, 1.385–7.279; P = 0.006) in patients
with colorectal cancer. Thus, lncRNA DANCR up-regulation is
associated with aggressive progression and poor prognosis in
colorectal cancer and may function as an independent marker
for predicting the clinical outcome of colorectal cancer patients.
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FIGURE 1 | LncRNAs as potential prognostic biomarkers for human colorectal cancer. A depiction of a sagittal view of the colorectal wall showing the
progression of lesions associated with CRC and the accompanying alterations in the observed expression levels for several lncRNAs.
However, further studies are needed to elucidate the mechanisms
of action of lncRNA DANCR in colorectal cancer.
FEZF1-AS1
FEZ family zinc finger 1 antisense RNA 1 (FEZF1-AS1) is a
recently identified lncRNA which is located in chr7q31.32 on
the opposite strand of gene FEZF1. Although its function in
normal or cancer cells is still unknown, Chen et al. (2016) have
recently identified significantly higher FEZF1-AS1 expression
levels in tumor tissues of CRC patients compared to adjacent
non-neoplastic mucosa tissues (P = 0.004). Specifically, in
patients diagnosed with lymph node metastases, the relative
mean expression of FEZF1-AS1 was over 2.30 fold higher than
in patients without metastases, indicating that FEZF1-AS1might
have a fundamental role in CRC metastasis. Moreover, the
authors reported that the up-regulation of lncRNA FEZF1-AS1
was significantly associated with aggressive phenotypes of CRC
and poor prognosis in patients with CRC when using Kaplan-
Meier analysis. High expression levels of FEZF1-AS1 in CRCwere
significantly correlated with overall survival (P = 0.002) and
disease-free survival (P = 0.002) of CRC patients, with high
levels of FEZF1-AS1 being associated with short survival times.
Further univariate and multivariate analyses indicated that high-
level expression of FEZF1-AS1 was an independent prognostic
factor of outcomes in patients with CRC (HR = 2.401, P =
0.035). In a further step, the authors showed that FEZF1-AS1
increases cell proliferation, migration and invasiveness by means
of in vitro studies in a panel of CRC cell lines. In addition,
FEZF1-AS1 down-regulation in vivo inhibited tumor growth and
metastasis, pointing to a promotional role of FEZF1-AS1 in CRC
tumorigenesis and progression. Thus, all the results together
suggest lncRNA FEZF1-AS1 as a putative prognostic biomarker
and a target for new therapies of CRC (Chen et al., 2016).
FTX
The FTX transcript is a conserved functional lncRNA encoded
within the X-inactivation center (XIC). This gene located in
chrXq13.2 harbors 4 miRNAs in its introns, the miR-374b/421
cluster and the miR-545/374a cluster. Guo X. B. et al. (2015)
measured lncRNA FTX expression in more than 100 CRC
samples and found that lncRNA FTX was significantly up-
regulated in CRC tissues compared with adjacent normal tissues.
High lncRNA FTX expression correlated with differentiation
grade, lymph vascular invasion and clinical stage. However, there
were no significant correlations with other clinicopathological
features, such as age, sex, tumor histology, perineural invasion,
tumor site, and lymph node metastasis. Multivariate regression
analysis indicated that the status of lncRNA FTX expression
was an independent predictor of overall survival, as well as
differentiation grade and clinical stage, indicating that lncRNA
FTXmay be a promising prognostic biomarker for CRC patients.
HOTAIR
HOX Transcript Antisense Intergenic RNA (HOTAIR) is a 2.2 kb
long non-coding RNA transcribed from the antisense strand of
HOXC gene cluster, which is located in chromosome 12q13, and
which takes part in the epigenetic regulation of gene expression
(Gupta et al., 2010). Several studies have shown that HOTAIR is
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TABLE 2 | Compilation of studies showing significant associations between the expression of lncRNAs with CRC clinicopathological features.
LncRNA Study
Design
Sample size
(cohort/validation)
Detection
method
lncRNA expression
in CRC
Clinicopathological
features associated to
CRC
Overall survival
rate
References
ONCOGENIC lncRNA
91H Cohort 72 qRT-PCR1 up-regulated Poor prognosis, DM HR = 3.66,
P = 0.001
Deng et al., 2014
CCAT1 Cohort 113 qRT-PCR, ISH up-regulated Progression, LNM, LM ND Alaiyan et al., 2013
CCAT1 Cohort 48 qRT-PCR1 up-regulated TNM stage, LNM, poor OS Kaplan-Meier
P < 0.001
He et al., 2014
CLMAT3 Cohort 30/90 qRT-PCR1 up-regulated LM, poor OS HR = 2.05, P = 0.02 Ye et al., 2015
DANCR Cohort 104 qRT-PCR1 up-regulated TNM stage, LNM HR = 2.131,
P = 0.009
Liu et al., 2015
FEZF1-AS1 Cohort 34 pairs / 153 qRT-PCR, ISH up-regulated TNM stage, LNM, DM HR = 2.401,
P = 0.035
Chen et al., 2016
FTX Cohort 35 pairs / 187 qRT-PCR up-regulated TNM stage, LI, VI HR = 2.37,
P = 0.00041
Guo X. B. et al.,
2015
HOTAIR Cohort 100 /320 qRT-PCR2, EA up-regulated LM, poor prognosis HR = 5.62,
P = 0.008
Kogo et al., 2011
HOTAIR Cohort 152 qRT-PCR1 up-regulated LNM HR = 3.915,
P = 0.021
Wu Z. H. et al., 2014
HOTAIR Meta-
analysis
2,033 qRT-PCR, EM up-regulated Poor prognosis *HR = 2.26 (95%CI:
1.62–3.15)
Zhang S. et al., 2014
HOTTIP Cohort 156 / 21 qRT-PCR1 up-regulated TNM stage, DM HR = 2.151,
P = 0.017
Ren et al., 2015
lncRNA-ATB Cohort 124 qRT-PCR2 up-regulated TS, IC, LI, VI, LNM Kaplan-Meier
P = 0.036
Iguchi et al., 2015
MALAT1 Cohort 147 qRT-PCR2 up-regulated Poor prognosis HR = 3.968,
P = 0.002
Zheng et al., 2014
MALAT1 Meta-
analysis
1033 qRT-PCR, ISH up-regulated Poor OS, LNM, DM HR = 2.05, P = 0.01 Wu et al., 2015
PCAT-1 Cohort 108 qRT-PCR1 up-regulated Poor prognosis and DM HR = 3.12, P = 0.007 Ge et al., 2013
PVT-1 Cohort 164 qRT-PCR2 up-regulated Poor prognosis HR = 2.532,
P = 0.016
Takahashi et al.,
2014
TUG1 Cohort 120 qRT-PCR up-regulated - Kaplan-Meier
P < 0.001
Sun et al., 2016
UCA1 Cohort 80 qRT-PCR1 up-regulated Poor prognosis Kaplan-Meier
P = 0.046
Han et al., 2014
UCA1 Cohort 54 qRT-PCR1 up-regulated Poor prognosis, LM, DM,
TNM
HR = 3.13,
P = 0.023
Ni et al., 2015
TUMOR SUPPRESSIVE lncRNA
GAS5 Cohort 66 qRT-PCR1 down-regulation Poor OS HR = 0.036,
P = 0.034
Yin et al., 2014
LINC01296 Meta-
analysis
160/541 EA down-regulation – HR = 0.43,
P = 0.001
Qiu and Yan, 2015
MEG3 Cohort 62 qRT-PCR1 down-regulation TNM stage, tumor invasion HR = 0.133,
P = 0.049
Yin et al., 2015
ncRAN** Cohort 80 qRT-PCR1 down-regulation – *HR = 3.872,
P = 0.024
Qi et al., 2015
ncRuPAR Cohort 105 qRT-PCR down-regulation – ND Yan et al., 2014
RP11-462C24.1 Cohort 86 qRT-PCR1 down-regulation Poor prognosis and DM HR = 0.056,
P < 0.005
Shi et al., 2014
TUSC7 Cohort 81 qRT-PCR1 down-regulation TS, TNM stage, DM HR = 3.201,
P = 0.019
Qi et al., 2013
Abbreviations: ISH, In-situ hybridization; EM, expression microarray; EA, Exon array; qRT-PCR, quantitative real-time PCR using SYBR Green (1) or probe-based detection (2); TNM,
tumor size, lymph node involvement, and distant metastasis classification; DM, distant metastasis; LNM, lymph node metastasis; OS, overall survival; LM, liver metastasis; TS, tumor
size; IC, colorectal wall invasion; LI, lymphatic invasion; VI, vascular invasion; HR, hazardous risk; P, p-value; 95%CI, 95% confidence interval; ND, not determined.
*Pooled data from a meta-analysis.
**The analysis was carried out considering only ncRAN transcript Nbla10727.
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dysregulated in many cancers, including colorectal carcinomas
(Gutschner and Diederichs, 2012; Wu Y. et al., 2014; Hajjari
and Salavaty, 2015). Kogo et al. (2011) measured HOTAIR
expression in 100 colon cancer tissue samples along with their
matched normal tissues and reported significant differences
between them. In addition, they detected a strong association
between high HOTAIR expression and liver metastasis and
poor patient prognosis. Moreover, cDNA microarrays from a
specific subgroup of CRC samples obtained by laser micro-
dissection suggested that HOTAIR expression induced genome-
wide re-targeting of the regulator Polycomb Repressive Complex
2 (PRC2). Furthermore, in vitro studies confirmed invasion
promotion by HOTAIR over-expression (Kogo et al., 2011). All
these studies suggest that changes in HOTAIR expression may
impact the expression of multiple genes by the loss of cooperation
with PRC2 complex, resulting in an increase of undifferentiated
cancer cells. Thus, HOTAIR is a valuable factor for colorectal
cancer prognosis. Moreover, HOTAIR can promote colorectal
cancer cell migration and invasiveness and may participate in
epithelial-mesenchymal transition. Further studies are warranted
to advance our understanding of the involvement of HOTAIR
in cancer development, since this lncRNA is a potential target
for cancer prevention and treatment (Wu Z. H. et al., 2014). A
total of 19 papers comprising 2033 patients were included into
this meta-analysis. The authors found that HOTAIR expression
was associated with a poorer prognosis in patients with different
types of cancer, as well as advanced pathological stage (Zhang
S. et al., 2014). Finally, Zhao et al. (2015) have recently found
levels of HOTAIR significantly higher in plasma of CRC patients
than that of the healthy controls. In the same study, the authors
also reported that plasma levels of HOTAIR were significantly
decreased in CRC patients after surgical treatment as compared
to pre-operative patients, confirming, all together, the potential
use of HOTAIR as a diagnostic biomarker for CRC.
HOTTIP
HOXA transcript at the distal tip (HOTTIP) is a∼3.8 kb lncRNA,
which is spliced and polyadenylated. This gene is located at 5′
end of HOXA cluster and regulates the transcription of HOXA
genes in vivo, which are collinearly expressed along the antero-
posterior axis (Wang et al., 2011). The coordinated expression
of HOTTIP and the adjacent HOXA genes has been observed in
normal cells, tumors and also cancer cell lines (Sasaki et al., 2007).
HOTTIP is expressed at low levels (∼0.3 copies/cell) in several
human tissues (colon, prostate, placenta, and uterus) and its
expression pattern seems to be conserved from development to
adulthood (Sasaki et al., 2007; Wang et al., 2011). A recent study
based on 156 CRC and 21 adjacent non-malignant tissues showed
that HOTTIP is expressed at significantly higher levels in CRC
than normal tissues (Ren et al., 2015). Interestingly, its expression
is correlated positively and significantly with T stage, clinical
stage and distant metastasis. Finally, the same authors indicate
that the increased expression of HOTTIP may be used as an
unfavorable prognosis predictor for CRC patients. A more recent
study confirmed that HOTTIP is involved in CRC (Lian et al.,
2015). The authors observed that the over-expression ofHOTTIP
is correlated with advanced pathological stage and larger tumor
size. Interestingly, the knockdown of HOTTIP in vivo inhibited
the growth of the tumor, suggesting that HOTTIPmay be a good
candidate for therapy of CRC.
LncRNA-ATB
A recent exploratory analysis performed in hepatocellular
carcinoma cell lines identified a new lncRNA altered upon
TGF-β activation, named lncRNA-activated by TGF-β (lncRNA-
ATB), that promotes invasion and metastasis through epithelial-
mesenchymal transition (Yuan et al., 2014). Characterization
analyses found that lncRNA-ATB is 2446 bp long and a BLAST
search of the sequence against the human genome showed
the presence of three highly homologous regions mapping on
chromosomes 13, 14, and 22. To further elucidate the functional
role of lncRNA-ATB in CRC, and its implication in invasion and
metastasis, a retrospective study used RT-qPCR to determine
the expression levels of lncRNA-ATB in a CRC tissue dataset.
The authors found that lncRNA-ATB expression was significantly
associated with tumor size, depth, lymphatic invasion, vascular
invasion, and lymph node metastasis. Therefore, lncRNA-ATB
may be involved in the progression of CRC and may be a
prospective biomarker for invasion and metastasis in CRC.
Although this result needs further validation in a larger cohort,
lncRNA-ATB could represent a molecular target for controlling
invasion-metastasis cascade in CRC (Iguchi et al., 2015).
MALAT1
Metastasis Associated Lung Adenocarcinoma Transcript 1
(MALAT1) is one of the most promising lncRNA in CRC
prognosis. It is an 8.75 kb long non-coding RNA transcribed
from the nuclear enriched transcript-2 (NEAT-2) gene, located
in chromosome 11q13. Initially associated to non-small cell
lung cancer metastasis, the over-expression of MALAT1 has
been further described in metastasis of various tumors as
hepatocellular carcinoma and endometrial stromal sarcoma (Ji
et al., 2003; Smolle et al., 2014). Initial in vitro studies performed
in CRC cell lines reported alterations in two fragments of the
lncRNA transcript. First, the over-expression of fragment 6918–
8441 nt that leads to proliferation and invasion promotion in
CRC cells lines. Second, a deletion of 5434–6951 nt fragment
that includes a key factor for normal cell functioning, and
whose absence contributes to carcinogenic processes (Xu et al.,
2011). Next, Yang et al. (2015) confirmed that MALAT1
expression was higher in human CRC cell lines derived from
metastasis compared to cells derived from primary CRC tissue.
Moreover, over-expression of the activated transcript in SW480
cells promoted cell colony formation, migration and invasion
mediated by PRKA (kinase anchor protein 9). The authors also
reported that MALAT1 expression was significantly higher in
tumors than in their matching normal tissues especially in CRC
tissues with lymph node metastasis (Yang et al., 2015). In this
regard, another study carried out using RT-qPCR and human
CRC tissues (stage II/III) confirmed that MALAT1 expression
was 2.26 times higher (P = 0.0004) in tumor vs. non-cancerous
tissue (Zheng et al., 2014). Besides, association analyses of
MALAT1 expression and patient’s prognostic factors such as
disease free survival and overall survival indicated thatMALAT1
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over-expression is correlated with poor prognosis in CRC
patients, whereas multi-variate analysis confirmed MALAT1 as
an independent prognostic risk factor. Recently, a meta-analysis
including 1216 participants reported a correlation between high
MALAT1 expression and three markers of cancer progression:
lymph node metastasis, distant metastasis and survival rate (Wu
et al., 2015). Overall, these data point to MALAT1 as a potential
independent marker of cancer metastasis and prognosis and as a
potential molecular target to control cancer metastasis.
PCAT-1
Prostate cancer-associated ncRNA transcript 1 (PCAT-1) is a
long intergenic non-coding RNA codified by a gene located in a
gene desert of chromosome 8q24, about 725 kb from the c-MYC
oncogene. PCAT-1 was discovered in 2011 by RNA-sequencing
and is implicated in prostate cancer progression (Prensner et al.,
2011). PCAT-1 is up-regulated in prostate cancer tumor tissues
and it has been shown to promote cell proliferation through
association with polycomb repressive complex 2 (PCR2) as a
transcriptional repressor. Moreover, down-regulation of PCAT-
1 by interference RNA was enough to reduce cell proliferation
in vitro, pointing to PCAT-1 as a potential therapeutic target of
prostate cancer (Prensner et al., 2014). So far, PCAT-1 expression
has been associated to few cancer types such as CRC, and
esophageal squamous carcinoma (Shi et al., 2015). Ge et al.
(2013) explored the potential use of PCAT-1 as a biomarker
for CRC diagnosis and therapy. For this, they analyzed the
expression levels of PCAT-1 by Real Time qPCR in 108 CRC
tumors and 81 matched controls (selected from 2003 to 2007),
and observed that PCAT-1 was frequently up-regulated in CRC
tissues compared with normal adjacent tissue, and that PCAT-1
was able to stratify overall survival and correlated with distant
metastasis in CRC patients. In addition, the over-expression
was unrelated to an increment of PCAT-1 gene copy number
variants. Multivariate analysis confirmed that PCAT-1 was an
independent prognostic factor (Ge et al., 2013). Therefore, PCAT-
1may be considered as a novel prognostic biomarker. Since CRC
prognosis may be influenced by PCAT-1, the authors suggested
that, once elucidated, themolecular mechanisms by which PCAT-
1 is involved in CRC progression may be useful as an adjuvant
therapy target.
PVT1
The human PVT1 oncogene (non-protein coding) is located
at 8q24. A wide variety of solid tumors carry amplification
of the 8q24 locus. Gain of supernumerary copies of the 8q24
chromosomal region has been shown to be common in many
human cancers and is associated with poor prognosis. Over-
expression of PVT1 has been suggested as a powerful predictor
of tumor progression and patient survival in a diverse range
of cancer types, such as pancreatic cancer (Huang et al., 2015),
gastric cancer (Kong et al., 2015), hepatocellular cancer (Ding
et al., 2015), ovarian and breast cancer (Guan et al., 2007).
Another remarkable feature of the PVT1 locus is that it resides
about 60 kb apart from the 3-prime of the well-known MYC
oncogene and that these two genes are co-amplified in CRC cell
lines (Shtivelman and Bishop, 1989; Tseng et al., 2014).
Takahashi et al. (2014) showed that PVT1 expression levels
in colorectal cancer tissues were significantly higher than those
in non-cancerous tissues. Knockdown of PVT1 significantly
inhibited colorectal cancer cells proliferation and reduced
invasive abilities compared with negative control cells. Moreover,
down-regulated PVT1 promotes colorectal cancer cells apoptosis.
The authors found that colorectal cancer patients with high PVT1
expression had a significantly poorer prognosis than those with
low PVT1 expression (P = 0.0101). Univariate and multivariate
analyses showed that PVT1 expression level was an independent
prognostic indicator of overall survival in patients with CRC
(relative risk: 2.532 P = 0.016; Takahashi et al., 2014).
TUG1
Taurine up-regulated gene 1 (TUG1) is a 9.7 kb gene mapping
to chromosome 22q12 that codifies a long non-coding RNA.
TUG1 is highly conserved in mammals, and was originally
detected in a genomic screen in taurine treated mouse retinal
cells (Young et al., 2005). In this study, the authors found
that TUG1 knockdown resulted in malformed or non-existent
outer segments of transfected photoreceptors through increased
apoptosis in the newborn retina. In humans, elevated levels
of TUG1 have been found in the caudate nucleus of patients
suffering from Huntington’s disease (Johnson, 2012), whereas
additional studies showed that lncRNA TUG1 was involved
in cancer progression, affecting apoptosis and proliferation in
several human tumor cells. Zhang et al. (2013) proved that
lncRNA TUG1 is generally up-regulated in osteosarcoma and
regulates proliferation and apoptosis of osteosarcoma cells. Han
et al. (2013) reported that high TUG1 expression levels were
associated with high grade and stage of urothelial carcinoma
of the bladder, whereas its silencing led to cell proliferation
inhibition and apoptosis induction. Recently, another study (Sun
et al., 2016) suggested that TUG1 could play a critical role in
CRC metastasis, and that it may serve both as a prognostic
biomarker and therapeutic target. After analyzing the expression
levels of TUG1 in 120 CRC patients, the authors observed an
up-regulation of the lncRNA in tumor tissue that in addition
was closely correlated with the survival time of the CRC
patients. Further in vitro analyses showed the oncogenic effect of
TUG1 over-expression in CRC cell lines. TUG1 over-expression
increased colony formation, migration and metastatic potential
in vivo. Besides, the authors showed that TUG1 activated EMT-
related gene expression.
UCA1
Urothelial Cancer Associated 1 (UCA1) is a lncRNA originally
identified in bladder transitional cell carcinoma (Wang et al.,
2006). The sequence of 7.37 kb is located in 19p13 chromosome.
The proliferative, migratory, invasive, and drug resistance
behaviors of human bladder TCC cell line BLS-211 were
enhanced by exogenous UCA1 expression in vitro (Wang
et al., 2006). UCA1 has been found significantly up-regulated
in most tumors and cancer cells, including colorectal cancer.
A multivariate survival analysis also indicated that UCA1
could be an independent prognostic marker in gastric cancer.
Han and collaborators found that UCA1 levels were markedly
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increased in colorectal cancer tissues and cells, and that they
influenced proliferation, apoptosis and cell cycle progression of
colorectal cancer cells (Han et al., 2014). In addition, the authors
assessed the correlation between UCA1 expression and various
clinicopathological data. They demonstrated that patients with
high UCA1 expression levels had a larger tumor size, less
differentiated histology and greater tumor depth as compared
to the low UCA1 expression group. Furthermore, patients with
high UCA1 expression had a significantly poorer prognosis
compared to patients with low UCA1 expression (P = 0.046).
Recently, Ni and colleagues reported that the expression of
UCA1 was statistically correlated with lymph node metastasis,
distant metastasis and tumor stage. Finally, patients with high
UCA1 expression had a poor prognosis and multivariate analysis
indicated thatUCA1 over-expression is an independent predictor
for CRC (Ni et al., 2015).
TUMOR SUPPRESSIVE LncRNAs
ASSOCIATED WITH PROGNOSIS IN
COLORECTAL CANCER
GAS5
First described as a tumor suppressor in 1988, the Growth
Arrest-Specific transcript 5 (GAS5) is a 630 nt long non-coding
transcript transcribed by a gene located in chromosome 1q25
(Schneider et al., 1988). Previous studies showed that GAS5 was
able to bind the glucocorticoid receptor (GR) in growth arrested
cells, influencing cell survival, metabolic regulation (Kino et al.,
2010), and apoptosis (Mourtada-Maarabouni et al., 2008) when
over-expressed. Conversely, GAS5 down-regulation has been
related to different types of cancer such as breast (Mourtada-
Maarabouni et al., 2009), prostate (Pickard et al., 2013), renal
cancer (Qiao et al., 2013), and more recently to cervical (Cao
et al., 2014), and gastric cancer (Guo X. et al., 2015). Regarding
CRC, Yin et al. (2014) observed that GAS5 is down-regulated
in human CRC tissues compared to the adjacent normal lung
tissues, and that lower levels of GAS5 are correlated with larger
tumor size, low histological grade and advanced TNM stage,
consistent with previous observations. Furthermore, the analysis
of GAS5 expression and prognosis showed that patients with
low levels of GAS5 had remarkably shorter survival time than
those with high levels (P < 0.001). Multivariate analysis revealed
that GAS5 expression was a significant independent predictor
of poor survival of CRC patients (P = 0.034), suggesting an
important role of GAS5 in CRC development and progression.
In order to confirm these results, the authors tested the effect of
GAS5 over-expression both in vitro (HCT-116 and DLD-1) and
in vivo (CRC xenografts mice) and observed that over-expression
of GAS5 could inhibit cell proliferation (Yin et al., 2014).
LINC01296
LINC01296 was identified by Qiu and Yan (2015) after re-
analyzing five Affymetrix Human Exon 1.0 ST published datasets
from Gene Expression Omnibus (GEO). In total 355 samples
were chosen to identify differentially expressed lncRNAs and
their potential as diagnostic biomarkers for CRC. Twenty-five
lncRNAs were differentially expressed between CRC tissue and
tumor-adjacent normal tissue samples. Among them, LINC01296
was shown to be significantly associated with the overall survival
of patients with CRC. Univariate and multivariate analysis
between expression levels of LINC01296 and TNM stages as
well as MSI (microsatellite instability) status indicated that
LINC01296 was a significant predictor of survival in CRC (P =
0.001) in addition to TNM stage (P = 0.001) and MSI status
(P = 0.006). These results were validated in an independent
series suggesting that LINC01296 could be a novel prognostic
biomarker for CRC (Qiu and Yan, 2015).
MEG3
Maternally Expressed Gene 3 (MEG3) gene is located in
chromosome 14q32, encodes a lncRNA and belongs to the
imprinted DLK1-MEG3 locus which contains some maternally
and paternally imprinted genes (Benetatos et al., 2011). It is
expressed in many normal tissues but multiple mechanisms
contribute to the loss of MEG3 expression in tumors, including
gene dosage and epigenetic changes. Strong evidence exists to
support that MEG3 is a lncRNA tumor suppressor (Zhou et al.,
2012). Yin et al. (2015) found that MEG3 expression is down-
regulated in CRC tumor tissue and that may regulate CRC cell
proliferation in vitro and in vivo. They also demonstrated that
MEG3 levels were remarkably correlated with histological grade,
deeper tumor invasion, and advanced TNM stage (P < 0.001).
Univariate and multivariate analyses show MEG3 expression as
an independent predictor for overall survival (Yin et al., 2015).
ncRAN
Non-coding RNA expressed in Aggressive Neuroblastoma
(ncRAN) is a long non-coding transcript mapping to
chromosome 17q25, a region of frequent gains in neuroblastoma
that harbors two transcripts (Nbla10727, Nbla12061). Initially,
it has been reported that high levels of ncRAN lncRNA were
significantly associated with poor neuroblastoma patient’s
outcome (Yu et al., 2009), as well as enhanced cell proliferation,
migration and invasion in bladder cancer cell lines (Zhu et al.,
2011). Conversely, recent studies performed in CRC reported
down-regulation of ncRAN in CRC fresh tumors and cell lines
compared with normal adjacent tissue and normal intestinal
mucosa cell line. Besides, reduced expression of ncRAN was
associated with poorly differentiated tumors, liver metastasis and
reduced overall survival rate. In vitro studies showed that ncRAN
may mediate cell invasion and migration of CRC cells with little
or no effect in cell proliferation, thus pointing to ncRAN as a
new potential early diagnostic biomarker (Smolle et al., 2014; Qi
et al., 2015). Overall, there is strong evidence that the expression
pattern of ncRNA is tumor-dependent.
ncRuPAR
ncRuPAR is a newly discovered long noncoding RNA molecule,
located in 5q13 chromosome, that can up-regulate protease-
activated receptor-1 (PAR-1) during embryonic growth. PAR-1
has been implicated in tumor growth, invasion, and metastasis in
several malignancies including colonic adenocarcinoma (Dorsam
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and Gutkind, 2007; Adams et al., 2015). Up-regulation of PAR-
1 expression has been found in gastric cancer (Liu et al., 2014),
invasive breast cancer, colon cancer (Darmoul et al., 2003),
and advanced stage prostate cancer (Wang et al., 2014). Adams
et al. (2015) established a functional role for thrombin and its
targets PAR-1 and fibrinogen in the pathogenesis of colonic
adenocarcinoma, supporting tumor growth as well as local
invasion and metastasis (Adams et al., 2015). Recently, the study
of Yan et al. (2014) found that ncRuPAR expression in CRC
tissues was statistically lower than in adjacent normal tissue.
Moreover, the authors reported that expression of ncRuPAR
was significantly correlated with lymph node metastasis, distant
metastasis, Dukes’ stage (Haq et al., 2009), differentiation, and
TNM stage (Yan et al., 2014). These findings suggest that
ncRuPAR could act as a biomarker for progression and prognosis
of CRC.
RP11-462C24.1
RP11-462C24.1 is a long non-coding RNA consisting of four
exons with a length of 1136 bp, located in chromosome 4q25
and with an unknown function. A prospective analysis screened
the aberrant expression of lncRNAs comparing CRC tumor
tissues and normal adjacent tissues, as well as CRC metastatic
tumors and non-metastatic tumors (Shi et al., 2014). Six lncRNAs
were selected for RT-qPCR validation in an independent cohort
of 86 CRC patients, based on their genomic location and
expression levels. Then, the authors explored the association of
RP11-462C24.1 expression with clinicopathological factors. The
analysis showed a decreased expression of the lncRNA RP11-
462C24.1 in tumor tissues compared with normal adjacent tissue
(P < 0.001).Moreover, RP11-462C24.1 expression was also lower
in CRC patients with metastasis than those without metastasis
(P < 0.049), and its low expression significantly correlated
with more distant metastasis (P < 0.011). Multivariate analysis
identified RP11-462C24.1 as an independent prognostic factor
for CRC (P < 0.005), whereas Kaplan-Meier analysis showed
that patients with low expression of RP11-462C24.1 had a poor
disease-free survival (P < 0.001). Overall, RP11-462C24.1 could
be considered a potential prognostic biomarker, providing a new
strategy for diagnosis. The study also implicates RP11-462C24.1
in the tumorigenesis and progression of CRC, and identifies it
as a potential target for further therapeutic studies (Shi et al.,
2014).
TUSC7
TUSC7, also known as LOC285194, is a lncRNA of 2105
nt in length located in chr3q13.31. It was first reported in
osteosarcoma samples and cell lines, where depletion of TUSC7
promoted proliferation of normal osteoblasts by regulation of
apoptotic genes and cell cycle transcripts. Recent studies showed
a potential tumor-suppressor role of this lncRNA in several
cancers such as esophageal squamous cell carcinoma (Tong et al.,
2014), pancreatic ductal adenocarcinoma (Ding et al., 2014) and
colorectal cancer (Qi et al., 2013). Liu et al. (2013) showed that
TUSC7 is a direct transcription target of p53, and that ectopic
expression of TUSC7 inhibits tumor cell growth both in vitro
and in vivo. Moreover, the authors determined the expression of
TUSC7 in colon cancer tissue by microarrays and showed that
TUSC7 was down-regulated in tumor specimens compared with
normal specimens. Finally, Qi et al. (2013) demonstrated that
relative expression levels of TUSC7 were lower in a cohort of 81
tumor tissues from CRC patients and CRC cell lines compared
to adjacent normal tissues and normal intestinal mucous cell
line. The authors also assessed the correlation between TUSC7
expression and clinicopathological data in CRC patients, and
found that low expression of TUSC7 was correlated with larger
tumor size, higher tumor stage, and more distant metastasis.
In addition, Kaplan-Meier analysis showed that patients with
low TUSC7 expression had a significantly poorer prognosis than
those with high TUSC7 expression (P = 0.010). All these data
indicate that this lncRNA could represent a good candidate
to consider as a potential biomarker for CRC prognosis and
development.
CONCLUSIONS AND FUTURE
PERSPECTIVES
Colorectal cancer is one of the most commonly diagnosed
cancers worldwide, and approximately half of all CRC patients
die from distant metastasis. Thus, the key to improve CRC
patients’ survival is early diagnosis and early prediction of
future metastasis. Diagnosis and prognosis markers are required
to select the best-suited treatment under preoperative or
postoperative conditions.
Advances in lncRNA expression profiling in human cancer
have highlighted their potential value as tumor biomarkers in
patient diagnosis and prognosis. Previous studies showed that
lncRNAs play an important role in regulating gene expression at
various levels, including chromatin modification, transcription,
and post-transcriptional processing. In addition, lncRNAs have
been reported to have tumor suppressor and oncogenic roles. In
particular, levels of several lncRNAs are correlated with TNM
stage, lymph node involvement, distant metastasis and overall
survival. This data indicates that lncRNAs could offer clinical
applications, both as diagnostic and prognostic markers, but also
as novel specific therapeutic targets.
Another advantage of lncRNAs is that they may be used in
clinics as minimally-invasive biomarkers due to their presence in
body fluids, such as urine and plasma or serum. For example,
HOTAIR and MALAT1 have been reported as diagnostic and
prognostic markers in the serum/plasma of cancer patients
(Svoboda et al., 2014; Kishikawa et al., 2015). In plasma, H19 is
differentially expressed in patients with gastric cancer compared
to healthy controls (Arita et al., 2013). Future studies on
circulating lncRNAs would allow us to identify lncRNAs as
putative minimally-invasive biomarkers for CRC. In this regard,
a challenging aspect is the low expression levels of some lncRNAs,
which brings about the need for using protocols based on
amplification and/or enrichment of the circulating molecules.
It is important to bear in mind that, although in this
review we have only focused and comprehensively described
the lncRNAs significantly associated to CRC prognosis, other
lncRNAs previously found dysregulated in CRC patients or
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associated to prognosis in other types of cancer should also be
considered in future studies when looking for biomarkers of CRC
prognosis. Among them, for example, Colon Cancer Associated
Transcript 2 (CCAT2) is overexpressed in microsatellite stable
CRC samples (Ling et al., 2013). Although a recent study failed
to detect CCAT2 in human CRC tissue or CRC cell lines (Xiang
et al., 2014), elevated expression of CCAT2 has been associated
with poor prognosis in a wide range of cancers, including
breast cancer (Redis et al., 2013), non-small cell lung cancer
(Qiu et al., 2014), gastric cancer (Wang C. Y. et al., 2015),
and esophageal squamous cell carcinoma (Zhang et al., 2015).
Another well-established up-regulated lncRNA associated with
CRC and other cancer types is Colorectal Neoplasia Differentially
Expressed gene (CRNDE). CRNDE is activated during early
steps of CRC development, and its expression is highly elevated
in colorectal adenomas and adenocarcinomas (Graham et al.,
2011). CRNDE was also reported to promote glioma cell growth
and invasion, being highly up-regulated both in patients with
glioma and in vitro cell lines (Wang Y. et al., 2015), and a
recent study showed evidence of CRNDE as a potential marker
of poor prognosis in women with ovarian carcinomas, with
different outcomes depending on the therapeutic regimen used
(Szafron et al., 2015). In addition, a very recent study (Esposti
et al., 2016) confirmed CRNDE as well as lncRNA H19, among
other known and new oncogenic lncRNAs, to be up-regulated
in patients with hepatocellular carcinoma when performing
RNA-Seq analyses in 23 liver tissues (controls, cirrhotic and
hepatocellular carcinomas). Indeed, increased levels of the H19
transcript have been observed in many cancers, including CRC
(Liang et al., 2015), suggesting that H19 and its gene products
may be involved in tumor progression although prognostic value
has not been proven so far. Thus, apart from the reviewed
lncRNAs clearly linked to CRC prognosis, several studies have
identified a large number of other lncRNAs that are dysregulated
in CRC (reviewed in Ragusa et al., 2015; Xie et al., 2015).
Since they may be potential prognostic biomarkers once their
sensitivities and specificities are established, we think they should
be taken into account in future analyses studying the possible role
and use of lncRNAs as prognostic biomarkers in CRC.
Taken together, the use of lncRNAs as CRC prognostic
biomarkers seems very promising. In the future, further
characterization of these lncRNAs and greater understanding
of their molecular function may support their clinical use for
improving cancer diagnosis, monitoring cancer progression and
as targeted therapies.
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